SCHEMBL712932

SCHEMBL712932

COc1ccc(OCc2ccccc2)cc1-c1nc2cccnc2[nH]1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.48
PDGFRB P09619 1/20 0.47
PDGFRA P16234 1/20 0.47
PRMT5 O14744 2/20 0.46
MAPT P10636 3/20 0.44
KDM4E B2RXH2 1/20 0.44
PDE4A P27815 2/20 0.42
PDE4B Q07343 2/20 0.42
PDE4C Q08493 2/20 0.42
PDE4D Q08499 2/20 0.42
MAPK1 P28482 1/20 0.42
PDE5A O76074 1/20 0.42
LMNA P02545 2/20 0.42
MAOB P27338 1/20 0.41
CCNB2 O95067 1/20 0.41
CDK1 P06493 1/20 0.41
CCNB1 P14635 1/20 0.41
GSK3A P49840 1/20 0.41
GSK3B P49841 1/20 0.41
CDK5 Q00535 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10206627 0.93 CYP3A4 (0.46) CYP3A4PDGFRBPDGFRAPRMT5PDE4A
SCHEMBL10206607 0.92 CYP3A4 (0.51) CYP3A4PDGFRBPDGFRAPRMT5PDE4A
SCHEMBL2668133 0.90 CYP3A4 (0.47) CYP3A4PDGFRBPDGFRAPRMT5MAPT
SCHEMBL10206608 0.89 SYK (0.46) CYP3A4PRMT5PDE4APDE4BPDE4C
SCHEMBL711187 0.89 CYP3A4 (0.46) CYP3A4PDGFRBPDGFRAPRMT5PDE4A
SCHEMBL10206615 0.87 IKBKB (0.47) CYP3A4PRMT5MAPTPDE4APDE4B
SCHEMBL711485 0.86 PDE2A (0.52) PDGFRBPDGFRAMAPTKDM4EMAPK1
SCHEMBL9071887 0.85 CYP3A4 (0.51) CYP3A4PRMT5PDE4APDE4BPDE4C
Trifluoroacetic Acid SCHEMBL711595 0.85 LRRK2 (0.43) CYP3A4PDE4APDE4BPDE4CPDE4D
SCHEMBL9071848 0.85 CYP3A4 (0.42) CYP3A4PDGFRBPDGFRAPRMT5KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1940837-B1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA PHARMACEUTICAL (JP) 2012-11-07 EP disclosed
US-8124617-B2 Imidazopyridine compounds TAKEDA SAN DIEGO, INC. (US) 2012-02-28 US disclosed
US-8124617-B2 Imidazopyridine compounds TAKEDA SAN DIEGO, INC. (US) 2012-02-28 US disclosed
US-8124617-B2 Imidazopyridine compounds TAKEDA SAN DIEGO, INC. (US) 2012-02-28 US disclosed
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA SAN DIEGO, INC. 2010-03-18 US disclosed
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA SAN DIEGO, INC. 2010-03-18 US disclosed
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA SAN DIEGO, INC. 2010-03-18 US disclosed
EP-1940837-A2 IMIDAZOPYRIDINE COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2008-07-09 EP disclosed
WO-2007028135-A2 IMIDAZOPYRIDINE COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-03-08 WO disclosed
WO-2007028135-A2 IMIDAZOPYRIDINE COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS GCK, GCKR, KHK CYP3A4 193/4885PDGFRB 3099/4885PDGFRA 3259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.